Northeast Pharmaceutical Group Co., Ltd. (SHE:000597)
China · Delayed Price · Currency is CNY 4.820
-0.090 (-1.83%)
May 20, 2026, 12:54 PM CST
SHE:000597 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 7,083 | 7,024 | 7,448 | 8,185 | 8,719 | 8,046 |
Other Revenue | 50.85 | 50.85 | 54.09 | 58.56 | 89.5 | 98.7 |
| 7,134 | 7,075 | 7,503 | 8,243 | 8,809 | 8,145 | |
Revenue Growth (YoY) | -5.00% | -5.70% | -8.98% | -6.42% | 8.15% | 10.30% |
Cost of Revenue | 4,798 | 4,645 | 4,741 | 5,125 | 5,557 | 5,056 |
Gross Profit | 2,336 | 2,430 | 2,761 | 3,118 | 3,252 | 3,089 |
Selling, General & Admin | 1,842 | 1,930 | 2,096 | 2,579 | 2,767 | 2,698 |
Research & Development | 174.32 | 172.27 | 117.76 | 97.04 | 160.39 | 83.46 |
Other Operating Expenses | 82.03 | 70.06 | 77.34 | 81.75 | 83.13 | 83.86 |
Operating Expenses | 2,098 | 2,172 | 2,285 | 2,752 | 3,032 | 2,879 |
Operating Income | 237.9 | 258.22 | 475.95 | 366.2 | 219.56 | 210.63 |
Interest Expense | -49.16 | -49.16 | -64.53 | -78.36 | -92.11 | -120.16 |
Interest & Investment Income | 97.13 | 98.48 | 133.79 | 163.69 | 93.88 | 110.25 |
Currency Exchange Gain (Loss) | -25.85 | -25.85 | 10.06 | 8.11 | 28.68 | -6.45 |
Other Non Operating Income (Expenses) | -50.72 | -37.99 | -49.15 | -54.94 | -37.85 | -47.68 |
EBT Excluding Unusual Items | 209.3 | 243.7 | 506.12 | 404.7 | 212.15 | 146.59 |
Impairment of Goodwill | -1.04 | -1.04 | - | - | - | - |
Gain (Loss) on Sale of Investments | -2.89 | 0.35 | - | - | - | - |
Gain (Loss) on Sale of Assets | 1.08 | 1.05 | 6.19 | 0.17 | 419.3 | 3.29 |
Asset Writedown | -0.33 | - | -10.12 | -3.9 | -7.97 | -28.96 |
Other Unusual Items | 61.2 | 61.2 | 91.72 | 87.21 | -98.04 | -0.76 |
Pretax Income | 267.32 | 305.26 | 593.91 | 488.17 | 525.44 | 120.16 |
Income Tax Expense | 68.5 | 87.43 | 170.63 | 112.19 | 168.28 | 24.72 |
Earnings From Continuing Operations | 198.82 | 217.83 | 423.28 | 375.98 | 357.16 | 95.44 |
Minority Interest in Earnings | 51.56 | 42.24 | -13.43 | -17.52 | -6.9 | 3.59 |
Net Income | 250.38 | 260.07 | 409.85 | 358.46 | 350.25 | 99.03 |
Net Income to Common | 250.38 | 260.07 | 409.85 | 358.46 | 350.25 | 99.03 |
Net Income Growth | -35.56% | -36.55% | 14.34% | 2.34% | 253.69% | 707.93% |
Shares Outstanding (Basic) | 1,432 | 1,445 | 1,413 | 1,434 | 1,401 | 1,415 |
Shares Outstanding (Diluted) | 1,432 | 1,445 | 1,413 | 1,434 | 1,401 | 1,415 |
Shares Change (YoY) | 1.11% | 2.23% | -1.43% | 2.34% | -0.97% | 15.42% |
EPS (Basic) | 0.17 | 0.18 | 0.29 | 0.25 | 0.25 | 0.07 |
EPS (Diluted) | 0.17 | 0.18 | 0.29 | 0.25 | 0.25 | 0.07 |
EPS Growth | -36.27% | -37.93% | 16.00% | - | 257.14% | 600.00% |
Free Cash Flow | 1,065 | 1,009 | 599.34 | 351.32 | 864.44 | 626.7 |
Free Cash Flow Per Share | 0.74 | 0.70 | 0.42 | 0.24 | 0.62 | 0.44 |
Dividend Per Share | 0.055 | 0.055 | 0.100 | 0.100 | 0.100 | 0.014 |
Dividend Growth | -45.00% | -45.00% | - | - | 614.29% | 75.00% |
Gross Margin | 32.75% | 34.35% | 36.81% | 37.83% | 36.92% | 37.93% |
Operating Margin | 3.33% | 3.65% | 6.34% | 4.44% | 2.49% | 2.59% |
Profit Margin | 3.51% | 3.68% | 5.46% | 4.35% | 3.98% | 1.22% |
Free Cash Flow Margin | 14.93% | 14.26% | 7.99% | 4.26% | 9.81% | 7.69% |
EBITDA | 737.56 | 767.86 | 1,025 | 911.39 | 754.38 | 722.45 |
EBITDA Margin | 10.34% | 10.85% | 13.67% | 11.06% | 8.56% | 8.87% |
D&A For EBITDA | 499.67 | 509.63 | 549.5 | 545.19 | 534.82 | 511.82 |
EBIT | 237.9 | 258.22 | 475.95 | 366.2 | 219.56 | 210.63 |
EBIT Margin | 3.33% | 3.65% | 6.34% | 4.44% | 2.49% | 2.59% |
Effective Tax Rate | 25.62% | 28.64% | 28.73% | 22.98% | 32.03% | 20.57% |
Revenue as Reported | 7,075 | 7,075 | 7,503 | 8,243 | 8,809 | 8,145 |
Advertising Expenses | - | - | - | - | 7.13 | 10.53 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.